Name | PT2977 |
---|
Description | PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. PT2977 is a potential treatment for Clear cell renal cell carcinoma (ccRCC) and von Hippel–Lindau (VHL) disease[1]. |
---|---|
Related Catalog | |
Target |
HIF-2α:9 nM (IC50) |
In Vitro | PT2977 potently and dose-dependently reduces mRNA levels of human cyclin D1, a target gene regulated by HIF-2α, and leads to rapid and dose-dependent reduction in EPO expression[1]. |
References |
Molecular Formula | C17H12F3NO4S |
---|---|
Molecular Weight | 383.34 |